top of page

AnaptysBio's CEO discusses recent 12 week RA data from the company's PD-1 depleter and agonist, rosnilimab, and previews other upcoming catalysts

Mar 18

Daniel Faga goes over the recently released rosnilimab RA data and previews a longer-term follow-up that will be out in the second quarter. Plus, ulcerative colitis data that will be out in the fourth quarter and the opportunity there. He also highlights the company's PD-1 for oncology that is commercialized by GSK.

Recent Posts

At an R&D event hosted by the company in Kendall Square today, Alloy Therapeutics' CEO Errik Anderson talks the latest in science regarding bispecifics, TCR mimics, genetic medicines, and more

At an R&D event hosted by the company in Kendall Square today, Alloy Therapeutics' CEO Errik Anderson talks the latest in science regarding bispecifics, TCR mimics, genetic medicines, and more

Oxford, UK based Greywolf Therapeutics is pursuing cancer and autoimmune indications by attempting to target T-cells at their first signal of activation - an approach the company leads the field on

Oxford, UK based Greywolf Therapeutics is pursuing cancer and autoimmune indications by attempting to target T-cells at their first signal of activation - an approach the company leads the field on

Brainomix, an Oxford, UK based company that uses AI to help front line physicians analyze CT scans for stroke damage and interstitial lung disease, announced an $18M series C raise today

Brainomix, an Oxford, UK based company that uses AI to help front line physicians analyze CT scans for stroke damage and interstitial lung disease, announced an $18M series C raise today

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsors

NYSE_logo_large_no reg_378x197 (1).png

Learn more about our sponsors

Sponsor Spotlight

At Savills, the Life Sciences Team specializes in helping biotech companies unlock their full potential by aligning real estate strategies with their scientific and business goals. As a leading global commercial real estate advisory firm, we focus exclusively on occupier services and tenant representation, acting as a trusted partner to some of the most innovative companies in the industry.

Visit Savills' Life Sciences Overview

bottom of page